OBJECTIVE: Several studies in vitro or in rodent models have suggested a potential relationship between angiotensin-converting enzyme (ACE) inhibition and the insulin-like growth factor 1 (IGF-1) axis. However, this relationship has only rarely been investigated in humans. The aim of the present cross-sectional study was to assess the association of ACE inhibitors with free IGF-1 and IGFBP-3 in the blood of older hypertensive adults. METHODS: Data are from the baseline evaluation of the IlSIRENTE study, which enrolled 364 subjects aged 80 or older. For the present study we selected a subpopulation of 264 hypertensive participants without congestive heart failure. Free IGF-1 and IGFBP-3 in the blood were measured by a radioimmunoassay method. Analyses of covariance were performed to evaluate the differences in free IGF-1 and IGFBP-3 levels according to the use of ACE inhibitors. RESULTS: The mean age of participants was 85.7 years (SD: 4.9), 170 (64%) were women and 123 (47%) were using an ACE inhibitor. Following adjustment for potential confounders, the concentration of free IGF-1 was slightly, but not significantly higher among ACE inhibitor users than among non-users (0.74 vs. 0.65 ng/mL; p=0.20). In contrast, ACE inhibitor users had a significantly higher IGFBP-3 serum levels than non-users (4821 vs. 4330 ng/mL; p=0.005). In addition, the concentration of IGFBP-3 was significantly higher among ACE inhibitors users than among non-users of antihypertensive drugs (p=0.02) and users of other antihypertensive drugs (p=0.01). CONCLUSION: Among hypertensive older adults, ACE inhibitors use is associated with higher IGFBP-3 levels.
OBJECTIVE: Several studies in vitro or in rodent models have suggested a potential relationship between angiotensin-converting enzyme (ACE) inhibition and the insulin-like growth factor 1 (IGF-1) axis. However, this relationship has only rarely been investigated in humans. The aim of the present cross-sectional study was to assess the association of ACE inhibitors with free IGF-1 and IGFBP-3 in the blood of older hypertensive adults. METHODS: Data are from the baseline evaluation of the IlSIRENTE study, which enrolled 364 subjects aged 80 or older. For the present study we selected a subpopulation of 264 hypertensiveparticipants without congestive heart failure. Free IGF-1 and IGFBP-3 in the blood were measured by a radioimmunoassay method. Analyses of covariance were performed to evaluate the differences in free IGF-1 and IGFBP-3 levels according to the use of ACE inhibitors. RESULTS: The mean age of participants was 85.7 years (SD: 4.9), 170 (64%) were women and 123 (47%) were using an ACE inhibitor. Following adjustment for potential confounders, the concentration of free IGF-1 was slightly, but not significantly higher among ACE inhibitor users than among non-users (0.74 vs. 0.65 ng/mL; p=0.20). In contrast, ACE inhibitor users had a significantly higher IGFBP-3 serum levels than non-users (4821 vs. 4330 ng/mL; p=0.005). In addition, the concentration of IGFBP-3 was significantly higher among ACE inhibitors users than among non-users of antihypertensive drugs (p=0.02) and users of other antihypertensive drugs (p=0.01). CONCLUSION: Among hypertensive older adults, ACE inhibitors use is associated with higher IGFBP-3 levels.
Authors: Mauro Di Bari; Lonneke V van de Poll-Franse; Graziano Onder; Stephen B Kritchevsky; Anne Newman; Tamara B Harris; Jeff D Williamson; Niccoló Marchionni; Marco Pahor Journal: J Am Geriatr Soc Date: 2004-06 Impact factor: 5.562
Authors: Shelly L Gray; Robert M Boudreau; Anne B Newman; Stephanie A Studenski; Ronald I Shorr; Douglas C Bauer; Eleanor M Simonsick; Joseph T Hanlon Journal: J Am Geriatr Soc Date: 2011-11-04 Impact factor: 5.562
Authors: Shelly L Gray; Andrea Z LaCroix; Aaron K Aragaki; Mary McDermott; Barbara B Cochrane; Charles L Kooperberg; Anne M Murray; Beatriz Rodriguez; Henry Black; Nancy F Woods Journal: J Am Geriatr Soc Date: 2009-02 Impact factor: 5.562
Authors: Tadashi Yoshida; A Michael Tabony; Sarah Galvez; William E Mitch; Yusuke Higashi; Sergiy Sukhanov; Patrice Delafontaine Journal: Int J Biochem Cell Biol Date: 2013-06-13 Impact factor: 5.085
Authors: Dung V Nguyen; Sergio Li Calzi; Lynn C Shaw; Jennifer L Kielczewski; Hannah E Korah; Maria B Grant Journal: Growth Horm IGF Res Date: 2013-04-08 Impact factor: 2.372
Authors: Xilin Yang; Hailu Zhao; Yi Sui; Ronald C W Ma; Wing Yee So; Gary T C Ko; Alice P S Kong; Risa Ozaki; Chun Yip Yeung; Gang Xu; Peter C Y Tong; Juliana C N Chan Journal: Diabetes Date: 2009-04-28 Impact factor: 9.461